Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Down 10.9 %

SXTP stock opened at $0.47 on Wednesday. 60 Degrees Pharmaceuticals has a 52 week low of $0.42 and a 52 week high of $7.20. The company has a fifty day simple moving average of $0.96 and a two-hundred day simple moving average of $1.09. The firm has a market capitalization of $3.48 million, a P/E ratio of -0.05 and a beta of 4.22.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow acquired 35,823 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average price of $1.27 per share, with a total value of $45,495.21. Following the transaction, the chief executive officer now directly owns 94,580 shares in the company, valued at approximately $120,116.60. This represents a 60.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 60,372 shares of company stock valued at $76,975. Company insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.